Simon Quick Advisors LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Simon Quick Advisors LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,120 shares of the biopharmaceutical company’s stock after purchasing an additional 1,214 shares during the quarter. Simon Quick Advisors LLC’s holdings in Gilead Sciences were worth $565,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Bellevue Group AG grew its position in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after acquiring an additional 7,093 shares during the last quarter. Quantinno Capital Management LP grew its position in Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after buying an additional 48,910 shares during the last quarter. Legal & General Group Plc grew its position in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the last quarter. IRON Financial LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at $830,000. Finally, Capital Investment Advisors LLC grew its position in Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 0.1 %

Shares of GILD stock opened at $93.04 on Thursday. The firm has a 50-day moving average price of $91.62 and a 200 day moving average price of $84.57. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a market capitalization of $115.95 billion, a price-to-earnings ratio of 1,033.78, a PEG ratio of 1.29 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock worth $42,130,461 in the last 90 days. 0.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. UBS Group boosted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, Bank of America restated a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.